Compositions and methods to inhibit stem cell and progenitor cell binding to lymphoid tissue and for regenerating germinal centers in lymphatic tissues
The present invention relates to compositions and methods of inhibiting stem cell binding to organs and tissues, including the blocking of stem cell binding to germinal centers present in lymph tissue. Disclosed are compositions and methods for regenerating germinal centers in lymphatic tissue. Included in the compositions are adjuvants, agonists to CD40, CD28 and the IL-21 receptor, and antagonist to CD20.
1. A method to augment the number of circulating autologous or allogeneic stem cells that can be attracted to a damaged tissue or organ comprising:
administering a therapeutic agent that contains dexamethasone base at a dose between about 3 mg/kg and 26 mg/kg to a subject having a damaged tissue or organ and active germinal centers within their lymphoid tissue, prior to or in conjunction with the administration of autologous or allogeneic stem cells such that the stem cells reach the circulation of the subject, wherein said therapeutic agent inhibits binding of the stem cells to germinal centers within said lymphoid tissue, wherein the therapeutic agent does not block the binding of the stem cells to the damaged organ or tissue, thereby augmenting the numbers of circulating stem cells that can be attracted to the target tissue or organ as compared to the numbers of circulating autologous and allogeneic stem cells in a subject without administering the therapeutic agent.
2. The method of claim 1 , wherein the autologous or allogeneic stem cells are selected from: multipotent and pluripotent stem cells.
3. The method of claim 1 , wherein the stem cells are selected from: mesenchymal, mesodermal, adipose, stromal vascular, induced pluripotent, embryonic, olfactory, limbal, and oval cells.
4. The method of claim 1 , wherein the therapeutic agent is administered to the subject between about 12 to about 96 hours prior to the administration of the stem cells.
5. The method of claim 1 wherein the lymphoid tissue is selected from: spleen, Peyer's patches and lymph nodes.
6. A method to augment the number of circulating autologous stem cells that can be attracted to a damaged tissue or organ comprising:
administering a therapeutic agent that is a glucocorticoid to a subject having a damaged tissue or organ and active germinal centers within their lymphoid tissue, wherein the subject does not require hematopoietic recovery due to treatment selected from: cancer therapy, non-myeloablative therapy, myeloablative therapy, chemotherapy, and radiation; wherein the therapeutic agent is administered prior to or in conjunction with the administration of autologous stem cells as a stem cell treatment such that the stem cells reach the circulation of the subject, wherein said therapeutic agent inhibits binding of the autologous stem cells to germinal centers within said lymphoid tissue, and wherein the therapeutic agent does not block the binding of the stem cells to the damaged organ or tissue, thereby augmenting the numbers of circulating stem cells that can be attracted to the target tissue or organ as compared to the numbers of circulating autologous and allogeneic stem cells in a subject without administering the therapeutic agent.
7. The method of claim 6 wherein the therapeutic agent is dexamethasone.
8. The method of claim 7 , wherein the dexamethasone is administered to the subject not before 3-4 days prior to the administration of the stem cells.
9. The method of claim 7 wherein the dexamethasone is administered at a dose between about 3 mg/kg and 26 mg/kg of dexamethasone base.
10. The method of claim 6 , wherein the stem cells are selected from: multipotent and pluripotent stem cells.
11. The method of claim 6 , wherein the stem cells are selected from: mesenchymal, mesodermal, adipose, stromal vascular, induced pluripotent, olfactory, limbal, and oval cells.
12. The method of claim 6 , wherein the lymphoid tissue is selected from: spleen, Peyer's patches and lymph nodes.
13. The method of claim 6 , wherein the therapeutic agent is administered to the subject not before 3-4 days prior to the administration of the stem cells.